Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Roberto Pili, Georg A. Bjarnason, Xavier Garcia-del-Muro, Jeffrey A. Sosman, Ewa Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin

Research output: Contribution to journalArticle

1627 Citations (Scopus)

Abstract

Purpose: A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. Patients and Methods: Seven hundred fifty treatment-naïve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN-α 9 MU subcutaneously thrice weekly. Overall survival was compared by two-sided log-rank and Wilcoxon tests. Progression-free survival, response, and safety end points were assessed with updated follow-up. Results: Median overall survival was greater in the sunitinib group than in the IFN-α group (26.4 v 21.8 months, respectively; hazard ratio [HR] = 0.821; 95% CI, 0.673 to 1.001; P = .051) per the primary analysis of unstratified log-rank test (P = .013 per unstratified Wilcoxon test). By stratified log-rank test, the HR was 0.818 (95% CI, 0.669 to 0.999; P = .049). Within the IFN-α group, 33% of patients received sunitinib, and 32% received other vascular endothelial growth factor - signaling inhibitors after discontinuation from the trial. Median progression-free survival was 11 months for sunitinib compared with 5 months for IFN-α (P < .001). Objective response rate was 47% for sunitinib compared with 12% for IFN-α (P < .001). The most commonly reported sunitinib-related grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%). Conclusion: Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.

Original languageEnglish (US)
Pages (from-to)3584-3590
Number of pages7
JournalJournal of Clinical Oncology
Volume27
Issue number22
DOIs
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Interferon-alpha
Survival
Disease-Free Survival
Hand-Foot Syndrome
sunitinib
Therapeutics
Survival Analysis
Nonparametric Statistics
Vascular Endothelial Growth Factor A
Fatigue
Diarrhea
Appointments and Schedules
Hypertension
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., ... Figlin, R. A. (2009). Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 27(22), 3584-3590. https://doi.org/10.1200/JCO.2008.20.1293

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. / Motzer, Robert J.; Hutson, Thomas E.; Tomczak, Piotr; Michaelson, M. Dror; Bukowski, Ronald M.; Oudard, Stéphane; Negrier, Sylvie; Szczylik, Cezary; Pili, Roberto; Bjarnason, Georg A.; Garcia-del-Muro, Xavier; Sosman, Jeffrey A.; Solska, Ewa; Wilding, George; Thompson, John A.; Kim, Sindy T.; Chen, Isan; Huang, Xin; Figlin, Robert A.

In: Journal of Clinical Oncology, Vol. 27, No. 22, 01.08.2009, p. 3584-3590.

Research output: Contribution to journalArticle

Motzer, RJ, Hutson, TE, Tomczak, P, Michaelson, MD, Bukowski, RM, Oudard, S, Negrier, S, Szczylik, C, Pili, R, Bjarnason, GA, Garcia-del-Muro, X, Sosman, JA, Solska, E, Wilding, G, Thompson, JA, Kim, ST, Chen, I, Huang, X & Figlin, RA 2009, 'Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma', Journal of Clinical Oncology, vol. 27, no. 22, pp. 3584-3590. https://doi.org/10.1200/JCO.2008.20.1293
Motzer, Robert J. ; Hutson, Thomas E. ; Tomczak, Piotr ; Michaelson, M. Dror ; Bukowski, Ronald M. ; Oudard, Stéphane ; Negrier, Sylvie ; Szczylik, Cezary ; Pili, Roberto ; Bjarnason, Georg A. ; Garcia-del-Muro, Xavier ; Sosman, Jeffrey A. ; Solska, Ewa ; Wilding, George ; Thompson, John A. ; Kim, Sindy T. ; Chen, Isan ; Huang, Xin ; Figlin, Robert A. / Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. In: Journal of Clinical Oncology. 2009 ; Vol. 27, No. 22. pp. 3584-3590.
@article{578ca3addefc4b548e330e40ac158cd5,
title = "Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma",
abstract = "Purpose: A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. Patients and Methods: Seven hundred fifty treatment-na{\"i}ve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN-α 9 MU subcutaneously thrice weekly. Overall survival was compared by two-sided log-rank and Wilcoxon tests. Progression-free survival, response, and safety end points were assessed with updated follow-up. Results: Median overall survival was greater in the sunitinib group than in the IFN-α group (26.4 v 21.8 months, respectively; hazard ratio [HR] = 0.821; 95{\%} CI, 0.673 to 1.001; P = .051) per the primary analysis of unstratified log-rank test (P = .013 per unstratified Wilcoxon test). By stratified log-rank test, the HR was 0.818 (95{\%} CI, 0.669 to 0.999; P = .049). Within the IFN-α group, 33{\%} of patients received sunitinib, and 32{\%} received other vascular endothelial growth factor - signaling inhibitors after discontinuation from the trial. Median progression-free survival was 11 months for sunitinib compared with 5 months for IFN-α (P < .001). Objective response rate was 47{\%} for sunitinib compared with 12{\%} for IFN-α (P < .001). The most commonly reported sunitinib-related grade 3 adverse events included hypertension (12{\%}), fatigue (11{\%}), diarrhea (9{\%}), and hand-foot syndrome (9{\%}). Conclusion: Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.",
author = "Motzer, {Robert J.} and Hutson, {Thomas E.} and Piotr Tomczak and Michaelson, {M. Dror} and Bukowski, {Ronald M.} and St{\'e}phane Oudard and Sylvie Negrier and Cezary Szczylik and Roberto Pili and Bjarnason, {Georg A.} and Xavier Garcia-del-Muro and Sosman, {Jeffrey A.} and Ewa Solska and George Wilding and Thompson, {John A.} and Kim, {Sindy T.} and Isan Chen and Xin Huang and Figlin, {Robert A.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1200/JCO.2008.20.1293",
language = "English (US)",
volume = "27",
pages = "3584--3590",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",

}

TY - JOUR

T1 - Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

AU - Motzer, Robert J.

AU - Hutson, Thomas E.

AU - Tomczak, Piotr

AU - Michaelson, M. Dror

AU - Bukowski, Ronald M.

AU - Oudard, Stéphane

AU - Negrier, Sylvie

AU - Szczylik, Cezary

AU - Pili, Roberto

AU - Bjarnason, Georg A.

AU - Garcia-del-Muro, Xavier

AU - Sosman, Jeffrey A.

AU - Solska, Ewa

AU - Wilding, George

AU - Thompson, John A.

AU - Kim, Sindy T.

AU - Chen, Isan

AU - Huang, Xin

AU - Figlin, Robert A.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Purpose: A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. Patients and Methods: Seven hundred fifty treatment-naïve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN-α 9 MU subcutaneously thrice weekly. Overall survival was compared by two-sided log-rank and Wilcoxon tests. Progression-free survival, response, and safety end points were assessed with updated follow-up. Results: Median overall survival was greater in the sunitinib group than in the IFN-α group (26.4 v 21.8 months, respectively; hazard ratio [HR] = 0.821; 95% CI, 0.673 to 1.001; P = .051) per the primary analysis of unstratified log-rank test (P = .013 per unstratified Wilcoxon test). By stratified log-rank test, the HR was 0.818 (95% CI, 0.669 to 0.999; P = .049). Within the IFN-α group, 33% of patients received sunitinib, and 32% received other vascular endothelial growth factor - signaling inhibitors after discontinuation from the trial. Median progression-free survival was 11 months for sunitinib compared with 5 months for IFN-α (P < .001). Objective response rate was 47% for sunitinib compared with 12% for IFN-α (P < .001). The most commonly reported sunitinib-related grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%). Conclusion: Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.

AB - Purpose: A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic renal cell carcinoma (RCC). Final survival analyses and updated results are reported. Patients and Methods: Seven hundred fifty treatment-naïve patients with metastatic clear cell RCC were randomly assigned to sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule or to IFN-α 9 MU subcutaneously thrice weekly. Overall survival was compared by two-sided log-rank and Wilcoxon tests. Progression-free survival, response, and safety end points were assessed with updated follow-up. Results: Median overall survival was greater in the sunitinib group than in the IFN-α group (26.4 v 21.8 months, respectively; hazard ratio [HR] = 0.821; 95% CI, 0.673 to 1.001; P = .051) per the primary analysis of unstratified log-rank test (P = .013 per unstratified Wilcoxon test). By stratified log-rank test, the HR was 0.818 (95% CI, 0.669 to 0.999; P = .049). Within the IFN-α group, 33% of patients received sunitinib, and 32% received other vascular endothelial growth factor - signaling inhibitors after discontinuation from the trial. Median progression-free survival was 11 months for sunitinib compared with 5 months for IFN-α (P < .001). Objective response rate was 47% for sunitinib compared with 12% for IFN-α (P < .001). The most commonly reported sunitinib-related grade 3 adverse events included hypertension (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%). Conclusion: Sunitinib demonstrates longer overall survival compared with IFN-α plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC. The overall survival highlights an improved prognosis in patients with RCC in the era of targeted therapy.

UR - http://www.scopus.com/inward/record.url?scp=68949145218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949145218&partnerID=8YFLogxK

U2 - 10.1200/JCO.2008.20.1293

DO - 10.1200/JCO.2008.20.1293

M3 - Article

C2 - 19487381

AN - SCOPUS:68949145218

VL - 27

SP - 3584

EP - 3590

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 22

ER -